Get started
Author

Huifeng Niu

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
2021 · D. Ross Camidge, Hye Ryun Kim, et al. · Journal of Thoracic Oncology · 417
PDF
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells
2005 · Ryan T Phan, Masumichi Saito, et al. · Nature Immunology · 359
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.
1995 · B. H. Ye, S. Chaganti, et al. · The EMBO Journal · 273
PDF
Tracking CD40 signaling during germinal center development
2004 · Katia Basso, Ulf Klein, et al. · Blood · 186
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
2019 · Taofeek K. Owonikoko, Huifeng Niu, et al. · Journal of Thoracic Oncology · 162
PDF
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2016 · Peter Brünker, Katharina Wartha, et al. · Molecular Cancer Therapeutics · 142
PDF
Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6
2003 · Laura Pasqualucci, Oxana Bereshchenko, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 139
Phosphorylation of the p34 subunit of human single-stranded-DNA-binding protein in cyclin A-activated G1 extracts is catalyzed by cdk-cyclin A complex and DNA-dependent protein kinase.
1994 · Z Q Pan, A A Amin, et al. · Proceedings of the National Academy of Sciences · 112
BCL6 Controls the Expression of the B7-1/CD80 Costimulatory Receptor in Germinal Center B Cells
2003 · Huifeng Niu, Giorgio Cattoretti, et al. · The Journal of Experimental Medicine · 103
PDF
A Selective Phosphatase of Regenerating Liver Phosphatase Inhibitor Suppresses Tumor Cell Anchorage-Independent Growth by a Novel Mechanism Involving p130Cas Cleavage
2008 · Sherif Daouti, Wen-hui Li, et al. · Cancer Research · 98
PDF
Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
2013 · Kevin R. Kelly, Thomas C. Shea, et al. · Investigational New Drugs · 81
PDF
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
2011 · Huisheng Wang, Sherif Daouti, et al. · Cancer Research · 76
Molecular Pathogenesis of B Cell Malignancy: the Role of BCL-6
1999 · R. Dalla-Favera, A. Migliazza, et al. · Current topics in microbiology and immunology · 69
BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
2012 · Brenden Chen, Christine Tardell, et al. · PLoS ONE · 66
PDF
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
2019 · Kenichi Iwai, Tadahiro Nambu, et al. · Science Advances · 65
The proto‐oncogene BCL‐6 in normal and malignant B cell development
2002 · Huifeng Niu · Hematological Oncology · 58
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
2015 · Huifeng Niu, Mark Manfredi, et al. · Frontiers in Oncology · 54
PDF
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
2009 · Lucy Lee, Huifeng Niu, et al. · Clinical Cancer Research · 40
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
2022 · Sai-Hong Ignatius Ou, Makoto Nishio, et al. · Journal of Thoracic Oncology · 35
PDF
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery
2021 · Kenichi Iwai, Tadahiro Nambu, et al. · Science Advances · 32
Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy
2009 · Sherif Daouti, Huisheng Wang, et al. · Cancer Research · 32
PDF
Enhancer 1 binding factor (E1BF), a Ku-related protein, is a growth-regulated RNA polymerase I transcription factor: association of a repressor activity with purified E1BF from serum-deprived cells.
1994 · H Niu, S T Jacob · Proceedings of the National Academy of Sciences · 29
Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
2010 · Sherif Daouti, Brian Higgins, et al. · Molecular Cancer Therapeutics · 28
BCL-6 and the Molecular Pathogenesis of B-Cell Lymphoma
1994 · R. Dalla-Favera, B.H. Ye, et al. · Cold Spring Harbor Symposia on Quantitative Biology · 27
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
2020 · D. Ross Camidge, Huifeng Niu, et al. · Journal of Clinical Oncology · 24
Works count: 68
Citation count: 2,857
H-index: 24
I10-index: 33
Year
Topic
Type